Breaking Down SG&A Expenses: Bio-Techne Corporation vs Xencor, Inc.

A Tale of Two Biotech Giants: Bio-Techne vs. Xencor

In the ever-evolving biotech industry, understanding the financial dynamics of key players is crucial. Bio-Techne Corporation and Xencor, Inc. have been at the forefront, showcasing distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 550%, reflecting its aggressive expansion and strategic investments. In contrast, Xencor's expenses grew by approximately 615%, indicating its rapid scaling and operational growth.

Bio-Techne's expenses consistently outpaced Xencor's, peaking at nearly 400 million in 2023, while Xencor reached around 53 million. This disparity highlights Bio-Techne's larger operational scale and market reach. However, the absence of 2024 data for Xencor suggests potential reporting delays or strategic shifts. As these companies continue to innovate, their financial strategies will be pivotal in shaping the biotech landscape.